WallStreetZenWallStreetZen

NYSE: JNJ
JOHNSON & JOHNSON Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

JNJ past earnings growth

How has JNJ's earnings growth performed historically?
Company
31.36%
Industry
97.28%
Market
92.76%
JNJ's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
JNJ's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
JNJ's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

JNJ past revenue growth

How has JNJ's revenue growth performed historically?
Company
12.67%
Industry
24.91%
Market
51.15%
JNJ's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
JNJ's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
JNJ's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

JNJ earnings and revenue history

Current Revenue
$94.9B
Current Earnings
$19.8B
Current Profit Margin
20.9%
JNJ's has demonstrated consistent long-term... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

JNJ Return on Equity

Current Company
27.5%
Current Industry
42%
Current Market
38.4%
JNJ's Return on Equity (27.5%)... subscribe to Premium to read more.
High Return on Equity Performance

JNJ Return on Assets

Current Company
11.1%
Current Industry
10.4%
JNJ is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

JNJ Return on Capital Employed

Current Company
15.81%
Current Industry
15.6%
JNJ has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

JNJ vs General Drug Manufacturer Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
JNJ$94.88B$28.60B$19.83B+5.62%+4.50%
PFE$92.37B$32.34B$24.97B+11.92%+29.91%
LLY$29.32B$8.37B$6.13B+6.32%+26.58%
ABBV$56.73B$24.70B$12.48B+16.69%+12.44%
MRK$53.98B$19.42B$14.18B+6.21%+28.84%
View Top General Drug Manufacturer Stocks

JNJ earnings dates

Next earnings date
Jul 19, 2022

JOHNSON & JOHNSON Earnings & Revenue FAQ

What were JNJ's earnings last quarter?

On Invalid Date, JOHNSON & JOHNSON (NYSE: JNJ) reported Q1 2022 earnings per share (EPS) of $1.96, up 16.6% year over year. Total JOHNSON & JOHNSON earnings for the quarter were $5.15 billion. In the same quarter last year, JOHNSON & JOHNSON's earnings per share (EPS) was $2.35.

What was JNJ's earnings growth in the past year?

As of Q2 2022, JOHNSON & JOHNSON's earnings has grown 31.36% year over year. This is 65.92 percentage points lower than the US Drug Manufacturers - General industry earnings growth rate of 97.28%. JOHNSON & JOHNSON's earnings in the past year totalled $19.83 billion.

What is JNJ's earnings date?

JOHNSON & JOHNSON's earnings date is Invalid Date. Add JNJ to your watchlist to be reminded of JNJ's next earnings announcement.

What was JNJ's revenue last quarter?

On Invalid Date, JOHNSON & JOHNSON (NYSE: JNJ) reported Q1 2022 revenue of $23.43 billion up 4.95% year over year. In the same quarter last year, JOHNSON & JOHNSON's revenue was $22.32 billion.

What was JNJ's revenue growth in the past year?

As of Q2 2022, JOHNSON & JOHNSON's revenue has grown 12.67% year over year. This is 12.24 percentage points lower than the US Drug Manufacturers - General industry revenue growth rate of 24.91%. JOHNSON & JOHNSON's revenue in the past year totalled $94.88 billion.
©2022 WallStreetZen
Company
AboutBlogPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContact
Stocks
Stock ScreenerStock ForecastHighest Earnings StocksBest Dividend Paying StocksStatisticsTrending StocksStock Market SectorsStock Market Industries
Analysts
Top Performing Analysts
Social
TwitterYouTube
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.